Peter Hunt, MD

Headshot of Peter Hunt
User Profile Photo

Peter Hunt, MD

User Profile Name
Co-Director, UCSF-Bay Area CFAR
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Peter Hunt is a Professor of Medicine in the Division of Experimental Medicine (DEM) at the University of California San Francisco. He also serves as Associate Chief for Research for the ZSFG-UCSF Department of Medicine, Co-Director of the UCSF-GIVI Center for AIDS Research (for basic and translational science), and as a member of the Leadership Committee of the UCSF AIDS Research Institute. He also recently completed terms as Interim Chief of the DEM and Chair of the ACTG Inflammation and End Organ Disease Transformative Science Group. His primary research focus is on the inflammatory consequences of HIV infection. His clinic-based translational research program seeks to understand the determinants of persistent immune activation both in the presence and the absence of antiretroviral therapy, and to assess the impact of immune activation on clinical outcomes. He collaborates extensively with a multi-disciplinary team of investigators to assess the impact of persistent immune activation despite viral suppression on mortality and chronic diseases associated with aging (i.e., cardiovascular disease) and conducts clinical trials of novel immune-based interventions designed to decrease immune activation. Dr. Hunt has also led a translational research program in Mbarara, Uganda, focused on the determinants of immune recovery during suppressive antiretroviral therapy in that setting. He also helped develop a large mucosal immunology program at Zuckerberg San Francisco General Hospital focused on the impact of HIV on gut-associated lymphoid tissue and the determinants of microbial translocation in HIV infection. In 2016, he started a laboratory in the DEM, focused on the immunologic consequences of asymptomatic CMV replication during treated HIV infection as well as the adaptive immune defects that persist in this setting in an effort to develop targets for interventions to reduce morbidity and mortality.

User Profile Bio

Displaying 201 - 225 of 318

  1. Lee SA, Sinclair E, Jain V, Huang Y, Epling L, Van Natta M, Meinert CL, Martin JN, McCune JM, Deeks SG, Lederman MM, Hecht FM, Hunt PW. Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis. 2014 Aug 01; 210(3):374-82.
  2. Byakwaga H, Boum Y, Huang Y, Muzoora C, Kembabazi A, Weiser SD, Bennett J, Cao H, Haberer JE, Deeks SG, Bangsberg DR, McCune JM, Martin JN, Hunt PW. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis. 2014 Aug 01; 210(3):383-91.
  3. Lee SA, Sinclair E, Hatano H, Hsue PY, Epling L, Hecht FM, Bangsberg DR, Martin JN, McCune JM, Deeks SG, Hunt PW. Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One. 2014; 9(2):e89444.
  4. Achenbach CJ, Buchanan AL, Cole SR, Hou L, Mugavero MJ, Crane HM, Moore RD, Haubrich RH, Gopal S, Eron JJ, Hunt PW, Rodriguez B, Mayer K, Saag MS, Kitahata MM, Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) . HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis. 2014 Jun; 58(11):1599-606.
  5. Dunham RM, Vujkovic-Cvijin I, Yukl SA, Broadhurst MJ, Loke P, Albright RG, Wong JK, Lederman MM, Somsouk M, Hunt PW, Martin JN, Deeks SG, McCune JM. Discordance between peripheral and colonic markers of inflammation during suppressive ART. J Acquir Immune Defic Syndr. 2014 Feb 01; 65(2):133-41.
  6. Yukl SA, Sinclair E, Somsouk M, Hunt PW, Epling L, Killian M, Girling V, Li P, Havlir DV, Deeks SG, Wong JK, Hatano H. A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells. AIDS. 2014 Jan 28; 28(3):439-42.
  7. Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, Hunt PW, Hatano H, Sowinski S, Muñoz-Arias I, Greene WC. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014 Jan 23; 505(7484):509-14.
  8. Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, Deeks S, Pancino G, Taulera O, Lichterfeld M, Delobel P, Saez-Cirion A, Lambotte O, ANRS CO18 HIV Controllers Cohort , Cascade Collaboration in Eurocoord , SCOPE Cohort , International HIV Controllers Study . Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. PLoS One. 2014; 9(1):e85516.
  9. Siedner MJ, Musinguzi N, Tsai AC, Muzoora C, Kembabazi A, Weiser SD, Bennett J, Hunt PW, Martin JN, Haberer JE, Bangsberg DR. Treatment as long-term prevention: sustained reduction in HIV sexual transmission risk with use of antiretroviral therapy in rural Uganda. AIDS. 2014 Jan 14; 28(2):267-71.
  10. Weiser SD, Palar K, Frongillo EA, Tsai AC, Kumbakumba E, Depee S, Hunt PW, Ragland K, Martin J, Bangsberg DR. Longitudinal assessment of associations between food insecurity, antiretroviral adherence and HIV treatment outcomes in rural Uganda. AIDS. 2014 Jan 02; 28(1):115-20.
  11. Seu L, Ortiz GM, Epling L, Sinclair E, Swainson LA, Bajpai UD, Huang Y, Deeks SG, Hunt PW, Martin JN, McCune JM. Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection. PLoS One. 2013; 8(12):e84091.
  12. Porter DW, Bradley M, Brown Z, Canova R, Charlton S, Cox B, Hunt P, Kolarik D, Lewis S, O'Connor D, Reilly J, Spanka C, Tedaldi L, Watson SJ, Wermuth R, Press NJ. The discovery of potent, orally bioavailable pyrazolo and triazolopyrimidine CXCR2 receptor antagonists. Bioorg Med Chem Lett. 2014 Jan 01; 24(1):72-6.
  13. Tsai AC, Bangsberg DR, Kegeles SM, Katz IT, Haberer JE, Muzoora C, Kumbakumba E, Hunt PW, Martin JN, Weiser SD. Internalized stigma, social distance, and disclosure of HIV seropositivity in rural Uganda. Ann Behav Med. 2013 Dec; 46(3):285-94.
  14. Josefsson L, von Stockenstrom S, Faria NR, Sinclair E, Bacchetti P, Killian M, Epling L, Tan A, Ho T, Lemey P, Shao W, Hunt PW, Somsouk M, Wylie W, Douek DC, Loeb L, Custer J, Hoh R, Poole L, Deeks SG, Hecht F, Palmer S. The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time. Proc Natl Acad Sci U S A. 2013 Dec 17; 110(51):E4987-96.
  15. Kulkarni S, Qi Y, O'hUigin C, Pereyra F, Ramsuran V, McLaren P, Fellay J, Nelson G, Chen H, Liao W, Bass S, Apps R, Gao X, Yuki Y, Lied A, Ganesan A, Hunt PW, Deeks SG, Wolinsky S, Walker BD, Carrington M. Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease. Proc Natl Acad Sci U S A. 2013 Dec 17; 110(51):20705-10.
  16. Asher AK, Santos GM, Evans J, Dokubo EK, Lee TH, Martin JN, Deeks SG, Tobler LH, Busch M, Hunt PW, Page K. Human leukocyte antigen B*57 does not fully explain hepatitis C clearance in HIV controllers. AIDS. 2013 Nov 13; 27(17):2691-6.
  17. Muñoz MA, Liu W, Delaney JA, Brown E, Mugavero MJ, Mathews WC, Napravnik S, Willig JH, Eron JJ, Hunt PW, Kahn JO, Saag MS, Kitahata MM, Crane HM. Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. . 2013 Nov 01; 64(3):254-60.
  18. Hatano H, Yukl SA, Ferre AL, Graf EH, Somsouk M, Sinclair E, Abdel-Mohsen M, Liegler T, Harvill K, Hoh R, Palmer S, Bacchetti P, Hunt PW, Martin JN, McCune JM, Tracy RP, Busch MP, O'Doherty U, Shacklett BL, Wong JK, Deeks SG. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog. 2013; 9(10):e1003691.
  19. Matthews LT, Kaida A, Kanters S, Byakwagamd H, Mocello AR, Muzoora C, Kembabazi A, Haberer JE, Martin JN, Bangsberg DR, Hunt PW. HIV-infected women on antiretroviral treatment have increased mortality during pregnant and postpartum periods. AIDS. 2013 Oct; 27 Suppl 1:S105-12.
  20. Tsai AC, Bangsberg DR, Bwana M, Haberer JE, Frongillo EA, Muzoora C, Kumbakumba E, Hunt PW, Martin JN, Weiser SD. How does antiretroviral treatment attenuate the stigma of HIV? Evidence from a cohort study in rural Uganda. AIDS Behav. 2013 Oct; 17(8):2725-31.
  21. Hunt PW, Lederman MM, Deeks SG. Response: Maraviroc intensification and microbial translocation. Blood. 2013 Sep 26; 122(13):2283-4.
  22. Mann JK, Byakwaga H, Kuang XT, Le AQ, Brumme CJ, Mwimanzi P, Omarjee S, Martin E, Lee GQ, Baraki B, Danroth R, McCloskey R, Muzoora C, Bangsberg DR, Hunt PW, Goulder PJ, Walker BD, Harrigan PR, Martin JN, Ndung'u T, Brockman MA, Brumme ZL. Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. Retrovirology. 2013 Sep 16; 10:100.
  23. Hatano H, Somsouk M, Sinclair E, Harvill K, Gilman L, Cohen M, Hoh R, Hunt PW, Martin JN, Wong JK, Deeks SG, Yukl SA. Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers. AIDS. 2013 Sep 10; 27(14):2255-60.
  24. Haberer JE, Kiwanuka J, Nansera D, Muzoora C, Hunt PW, So J, O'Donnell M, Siedner M, Martin JN, Bangsberg DR. Realtime adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013 Aug 24; 27(13):2166-8.
  25. Lok JJ, Hunt PW, Collier AC, Benson CA, Witt MD, Luque AE, Deeks SG, Bosch RJ. The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy. AIDS. 2013 Aug 24; 27(13):2101-10.